Inhibition of c-kit receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor

Blood

Volumn 96, Issue 3, 2000, Pages 925-932

  Heinrich, Michael C ^a,b   Griffith, Diana J ^a   Druker, Brian J ^a   Wait, Cecily L ^a   Ott, Kristen A ^a   Zigler, Amy J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b R and D 19 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0034254249     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.925.015k50_925_932     Document Type: Article

References (78)

1. Human proto-oncogene c-kit a new cell surface receptor tyrosine kinase for an unidentified ligand
2. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
3. STK-1* the human homolog of Flk-2/Flt-3 is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
4. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: A comparison of control and Ws/Ws mutant rats
5. Hereditary anemias of the mouse: A review for geneticists
6. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - Evidence for an impaired c-kit kinase in mutant mice
7. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues
8. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors
9. Effects of rrSCF on multiple cytokine responsive HPP CFC generated from SCA+Lin-murine hematopoietic progenitors
10. Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells
11. Requirement for mast cell growth factor for primordial germ cell survival in culture
12. Induction of mast cell proliferation maturation and heparin synthesis by the rat c-kit ligand stem cell factor
13. Impaired development of interstitial cells and intestinal electrical rhythmicity in steal mutants
14. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity
15. Constitutive expression of steal factor gene by human stromel cells
16. Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF)
17. Stem cell factor and hematopoieals
18. C-kit ligand and flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
19. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer
20. Autocrine growth of small cell lung cancer mediated by co-expression of c-kit and stem cell factor
21. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells
22. Activating c-kit gene mutations in human germ cell tumors
23. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
24. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
25. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors
26. Activating mutations of c-kit at Asp816 are associated with constitutive activation of Stat signal transduction pathways in acute myeloid leukemia
27. In vivo differentiation of mast cells from acute myaloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation
28. Stem cell factor suppresses apoptosis in neuroblastoma cell lines
29. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins
30. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
31. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
32. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myalogenous leukemia
33. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myalogenous leukemia patients
34. Selective platalet-derived growth factor receptor kinase blockers reverse sis-transformation
35. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains
36. Purification of tryptase from a human mast cell line
37. Identification of mutations in the coding sequence of the proto- oncogene c-kit in a human mast cell leukemia cell line causing ligand- independent activation of c-kit product
38. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3
39. Establishment of an immature mast cell line from a patient with mast ceil leukemia
40. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuciear cells of patients who have mastocytoals with an associated hematologic disorder
41. The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells
42. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells under-going apoptosis
43. A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population
44. Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e
45. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product
46. Mutations in exon 11 0f c-kit occur preferentially in malignant versus benign gastrointestinal tumors and do not occur in lelomyomas or lelomy osarcomas
47. Activating and dominant inactiviting c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis
48. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
49. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors
50. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast call neoplasms
51. Atransforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain
52. Oncogenic mutation in the Kit receptot tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
53. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit- associated PI 3-kinase activity in COS-1 cells
54. Comparative analysis of signaling pathways between mast cell growth factor (c-kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factor-dependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating protein and mitogen-activated protein kinase
55. Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor- mediated proliferation, survival and cell adhesion in mast cells
56. Granulocyte-macrophage colony-stimulating factor, intedeukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase
57. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor
58. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinosltol 3-kinase
59. Retroviral mediated gene transduction of c-kit into single hematopoietic progenitor cells from cord blood enhances erythroid colony formation and decreases sensitivity to inhibition by TNF-α and TGF-β1
60. + CD38- bone marrow cells with multi-lineage potential at the single-cell level: Key role of thrombopoietin
61. The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136
62. Akt phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery
63. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
64. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
65. Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of sub-class III
66. An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: Auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis
67. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer
68. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene
69. Expression of stem cell factor and c-kit in human neuroblastoma
70. Specific repression of granulocyte-macrophage colony-stimulating factor gene expression in interleukin-1 stimulated endothelial cells with antisense oligodeoxynucleotides
71. Binding, uptake, and intracellular trafficking of phosphorothioate- modified oligodeoxynucleotides
72. COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth
73. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior
74. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
75. Ultrastructural characterization of interstitial cells of Cajal in the rat small intestine using control and Ws/Ws mutant rats
76. Testicular cancer
77. Response of severe systemic mastocytosis to interferon alpha
78. Contrast of response to D-MAP + Sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas [abstract]